News
Study: Early Treatment with Pegylated Interferon Lambda for Covid-19. Image Credit: NIAID Background Type III IFNs represent the first line of defense in upper respiratory tract (URT) infections ...
Participants in the pegylated interferon lambda group also had shorter time to hospitalization for COVID-19 (HR = 0.57; 95% CI, 0.33-0.95) and fewer deaths (HR = 0.39; 95% CI, 0.05-1.95) compared ...
Pegylated interferon may be considered the first choice of treatment for patients with chronic hepatitis B infection. This therapy has been shown to be superior to both conventional interferon as ...
Pegylated interferon lambda showed excellent efficacy and tolerability in treating hepatitis C, compared with pegylated interferon alfa-2a. Data on sustained virologic responses are still needed.
Meeting Coverage > EASL Bulevirtide/Pegylated Interferon Combo Beats Monotherapy for Chronic Hepatitis D — Combo therapies for HDV with drugs other than pegylated interferon would be better ...
Forty-three virally suppressed, HBeAg negative cHBV patients were enrolled in the clinical trial and received a lead-in of AB-729 (60mg every 8 weeks) plus nucleos (t)ide analog (NA) therapy for ...
Purpose We conducted a phase II study of pegylated interferon alfa-2a (PEG-IFN-α-2a) in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Patients and Methods Seventy-nine ...
The results, demonstrated in a clinical trial of nearly 2,000 patients, rivaled those achieved by Paxlovid. And the interferon shots hold even bigger promise, scientists said.
PURPOSE: The efficacy of interferon alfa has been established in treating advanced melanoma and renal cell carcinoma (RCC) patients. We conducted a phase I/II study to determine the maximum-tolerated ...
Background. We studied whether 48 weeks of pegylated interferon alfa-2b (peginterferon) add-on therapy increases serological response in hepatitis B virus (HBV) envelope antigen (HBeAg)–positive ...
Key details and takeaways from the presentation are as follows: Abstract 1086: " NKTR-288, a PEGylated Interferon Gamma Drug Candidate for the Treatment of Cancer ", Hamel, D., et al.
The patients received the pegylated long-acting interferon for 7.5 years, and 61% of the study population attained complete hematologic response, defined as hematocrit <45% without phlebotomy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results